Purple Biotech announces significant efficacy results from Phase 2 CM24 study

Purple Biotech (PPBT) announced that a poster presentation titled “Final analysis of the randomized Phase 2 cohort of CM24 with nivolumab and chemotherapy in pancreatic cancer & potential serum biomarkers” is being presented during the session “Liquid Biopsy: Circulating Nucleic Acids 4 / Predictive Biomarkers 1” at the Annual Meeting of the American Association of Cancer Research, AACR 2025, on Wednesday, April 30, 2025. Statistically significant efficacy in biomarker subgroup analyses was observed: 78% reduction in risk of death and 81% reduction in risk of progression or death in defined pretreatment ranges of serum or tumor CEACAM1 subgroup; 61% reduction is risk of death and 72% reduction in risk of progression or death in defined pretreatment ranges of serum CEACAM1 or myeloperoxidase subgroup; 90% reduction is risk of death and 81% reduction in risk of progression or death in high tumor CEACAM1 and low PD-L1 combined positive score subgroup